Treatment of Parkinson's disease with amantadine and L-Dopa.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D010919:Placebos; D011379:Prognosis
D004338:Drug Combinations; D010648:Phenylacetates; D010919:Placebos; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D000469:Alkaline Phosphatase